Nurix Therapeutics, Inc.
Clinical trials sponsored by Nurix Therapeutics, Inc., explained in plain language.
-
New drug cocktail aims to outsmart tough blood cancers
Disease control Not yet recruitingThis study tests a new drug, NX-5948, combined with other medicines (venetoclax and possibly rituximab or obinutuzumab) in adults with B-cell cancers such as lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. The goal is to see if the combination is safe and …
Phase: PHASE1, PHASE2 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
New hope for Tough-to-Treat blood cancers: phase 3 trial launches
Disease control Not yet recruitingThis study tests a new drug, NX-5948, against another drug, pirtobrutinib, in people with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding to prior treatment. About 620 adults whose cancer progressed after a previous BTK inhibitor…
Phase: PHASE3 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 19, 2026 11:48 UTC